JENNIFER WATSON: Open Payments
NPI 1750344834 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,193 in 125 payments from 18 companies in 2025. Trend: 2023 $1,181 · 2024 $5,360 · 2025 $10,193
Consulting: $6,479Food & beverage: $2,317Travel & lodging: $1,364Education: $34
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 13 | $8,197 |
| AstraZeneca Pharmaceuticals LP | 17 | $429 |
| GlaxoSmithKline, LLC. | 23 | $339 |
| GENZYME CORPORATION | 14 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $200 |
| Novartis Pharmaceuticals Corporation | 17 | $177 |
| BioCryst US Sales Co., LLC | 3 | $93 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Lilly USA, LLC | 3 | $72 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
Products named: Andembry, TEZSPIRE, DUPIXENT, NUCALA, CUVITRU, TRELEGY ELLIPTA, ORLADEYO, Hizentra.
Industry payments across ID — which companies pay providers there.
